Army to Study Use of Off-Label Meds for PTSD


The Army will launch a major research initiative next year on the effectiveness of commonly prescribed medication for PTSD. Speaking at the APA meeting in Philadelphia on Monday, Army Maj. Gary Wynn of Walter Reed and Col. David Benedik, associate director for the Center for the Study of Traumatic Stress at the Uniformed Services University of the Health Sciences, said clinical trials will evaluate medications such as Cymbalta, mirtazapine, prazosin, and atypical antipsychotics like Seroquel.

Abstract → 

Related Item:
Army to study use of ‘off label’ drugs to treat PTSD (Stars and Stripes)


Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.


Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.

Previous articleMy “Head in a Bucket” Metaphor
Next articleDisconnect Between Antipsychotic Prescribing and Metabolic Screening
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected].